All In Biotech

Drug Trial Radar · NCT06625710

Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

A Randomized, Double-blind, Placebo Controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics After Single and Multiple Administration of GV1001 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Oct 8, 2024

Primary completion

Aug 25, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
GemVax & KaelIndustry
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the the safety, tolerability and pharmacokinetic characteristics after single and multiple administration of GV1001 in healthy subjects. The main questions it aims to answer are: Safety and Tolerability of GV1001 in different dose scheme, and PK Characteristics of GV1001 in differenct dose scheme Part A: single dose, 8 days clinical trial participation including one 3-day hospitalization Part B \& Extra Cohort: Multiple dose, 42 days clinical trial participation (12 days treatment + 30 days safety follow-up) including two times of 3-day hospitalization.

Conditions

  • Neuro-Degenerative Disease

Interventions

  • GV1001Drug

    Lyophilized peptide from hTERT

  • PlaceboDrug

    0.9 % Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of GV1001Time frame: 6 weeks
  2. PK Characteristics of GV1001Time frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.